Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder

Current Medical Research and Opinion

Volumn 23, Issue 11, 2007, Pages 2805-2814

  Zhu, Baojin ^a   Kulkarni, Pandurang M ^a   Stensland, Michael D ^a   Ascher Svanum, Haya ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Atypical antipsychotics; Bipolar disorder; Costs; Olanzapine

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; GABAPENTIN; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ADOLESCENT; ADULT; BILLING AND CLAIMS; BIPOLAR DISORDER; CONFERENCE PAPER; CONTROLLED STUDY; DATA BASE; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DRUG COSTS; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 36348944629     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X233322     Document Type: Conference Paper

References (30)

1. Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003;64:53-9
2. Manning JS. Burden of illness in bipolar depression. Prim Care Companion J Clin Psychiatry 2005;7:259-67
3. Woods SW. The economic burden of bipolar disease. J Clin Psychiatry 2000;61:38-41
4. Murray CJ, Lopez AD. (eds.) The Global Burden of Disease: A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard University Press, 1996
5. Kleinman L, Lowin A, Flood E, et al. Costs of bipolar disorder. Pharmacoeconomics 2003;21:601-22
6. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press, 1990
7. Peele PB, Xu Y, Kupfer DJ. Insurance expenditures on bipolar disorder: clinical and parity implications. Am J Psychiatry 2003;160:1286-90
8. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness: 1991. Soc Psychiatry Psychiatr Epidemiol 1995;30:213-19
9. Chengappa KN, Suppes T, Berk M. Treatment of bipolar mania with atypical antipsychotics. Expert Rev Neurother 2004;4(6 Suppl 2):S17-25
10. Keck PE Jr. The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania. J Clin Psychiatry 2005;66:1333-4
11. American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder (Revision). Am J Psychiatry 2002;159(Suppl):1-50
12. Ghaemi SN, Ko JY. Polypharmacy of bipolar disorder. In: Ghaemi SN, ed. Polypharmacy in Psychiatry. New York: Marcel Dekker, 2002:35-78
13. Sachs G, Mullen JA, Devine NA, et al. Quetiapine versus placebo as adjunct to mood stabilizer for the treatment of acute bipolar mania. 15th Congr Eur Coll Europsychopharmacol; October 5-9, 2002; Barcelona, Spain: Abstr
14. Sachs G, Chengappa KNR, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004;6:213-23
15. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62-9
16. Yatham LN, Binder C, Riccardelli R, Leblanc, et al. Risperidone in acute and continuation treatment of mania. Int Clin Psychopharmacol 2003;18:227-35
17. Yatham LN, Kennedy SH, O'Donovan C. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006;8:721-39
18. Fleurence RL, Dixon JM, Revicki DA. Economics of atypical antipsychotics in bipolar disorder: a review of the literature. CNS Drugs 2006;20:591-9
19. Bridle C, Palmer S, Bagnall AM, et al. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technol Assess 2004;8(19)iii-iv:1-187
20. Gianfrancesco F, Pesa J, Wang RH. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. J Manag Care Pharm 2005;11:220-30
21. Gianfrancesco F, Wang RH, Pesa J. Relationship between initial quetiapine dose and effectiveness as reflected in subsequent mental health service use among patients with schizophrenia or bipolar disorder. Value Health 2006;8:471-8
22. Namjoshi MA, Rajamannar G, Jacobs T, et al. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania: results from a randomized controlled trial. J Affect Disord 2002;69:109-18
23. Revicki DA, Paramore LC, Sommerville KW, et al. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry 2003;64:288-94
24. Zhu B, Tunis S, Zhao Z, et al. Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial. Curr Med Res Opin 2005;21:555-64
25. American Medical Association. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). American Medical Association, 2006
26. Moran JL, Solomon PJ, Peisach AR, Martin J. New models for old questions: generalized linear models for cost prediction. J Eval Clin Pract 2007;13:381-9
27. SAS Institute Inc. SAS/STAT User's Guide, Version 8, Volume 1. Cary, NC: SAS Institute Inc., 1999
28. Ghaemi S. New treatments for bipolar disorder: the role of neuroleptic agents. J Clin Psychiatry 2000;61(Suppl 14):33-42
29. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment of chronic schizophrenia. Am J Psychiatry 2006;163:2080-9
30. Lieberman JA, Stroup S, McEvoy J, et al. Clinical antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Eng J Med 2005;353:1209-23